A Partnership Designed to Address Bottlenecks in Studies



Site Identification and Study Start Up	 Lack of data-driven feasibility assessments leads to unprepared and overloaded sites. Inconsistent investigator and site staff training delays site activation and increases compliance risk.
Recruitment	 80% of trials fail to meet enrollment targets. Finding the right participants for niche indications (oncology, rare disease).
Regulatory Challenges	 Complex and evolving regulatory requirements causes submission delays. 60% of studies require a protocol amendment and a lack of internal expertise leads to missteps and resubmissions.

Studies Are Becoming Longer and More Complex, While Historical Challenges in the Industry Continue







Macro Trends Continue:

66%

Of Investigators Participate in only 1 clinical trial 85%

Of Sites Fail to Meet Enrollment Targets and Timelines

42%

Increase in Procedures Required in Phase III Trials¹ 37%

Increase in Average Number of Planned Study Visits per Participant in Phase III Trials¹

An Ecosystem that Operates at the Center of Clinical Research




Driving Efficiencies by Connecting and Aligning Stakeholders

Participants & Patient Advocacy Groups

- 2.5MM+ Participants in WCG-Supported Studies
- Advocacy Group relationships across therapeutic areas

Sites & Institutions

- 3,600+ Institutions & Academic Medical Centers
- 250,000+ Investigators
- 300,000+ Sites
- 80,000 Clinical Research Coordinator Relationships



Sponsors & CROs


- 4,000+ Small & Mid-Cap
 BioPharma
- ~200 Small/Mid CROs
- 200+ Quality Consortium members, including small and mid-sized biotech

WCG's Expertise

wcg™

FDA Approved Drug Trials Supported by WCG (2019-2024)

Oncology	1522
CNS	437
Infectious	268
Hematology	138
Cardiovascular	132
Gastroenterology	121
Metabolic	113
Ophthalmology	112
Immunology	85
Dermatology	80
Respiratory	75
	'



Source: WCG ClinSphere™ © WCG Clinical 2025. All rights reserved.

Key Solutions to Help Ensure Your Milestones Are Met



Six Key Areas Emerging Biotech Companies Are Most Frequently Challenged By:



Study Planning

Design scientifically sound protocols to optimize study outcomes while helping to ensure compliance with evolving regulations.



Data-driven approach to identify topperforming sites that align with your protocol's specific needs



Site Training

Optimize site performance with live and on demand training for investigators and sites



Recruitment & Retention

Design participant recruitment strategies that reflect your study's unique requirements

Ethical & Regulatory Review

Complete IRB and IBC capabilities, ensuring fast, compliant, and ethical reviews




Statistical Consulting

Trusted consulting and advice to ensure your trial data us robust, valid, and regulatory-ready

Current Infectious Disease Vaccine Landscape




And WCG Support in the Last 5 Years



Infectious Disease Vaccine Landscape



Top Sponsors and U.S. Sites



Site	# of Trials
Velocity Clinical Research, Omaha, 68134	71
/elocity Clinical Research, Norfolk, 68701	51
Rochester Clinical Research Inc, Rochester, 14609	50
DM Clinical Research, Tomball, 77375	48
CenExel RCA, Hollywood, 33024	46
Henan Province Disease Prevention and Control Center, Zhengzhou	43
Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009	43
Johnson County Clin-Trials, Lenexa, 66219	43
Velocity Clinical Research, Savannah, 31406	40
Coastal Carolina Research Center, North Charleston, 29405	34
Flourish Research, San Antonio, 78229	33
Velocity Clinical Research, Sioux City, 51106	33
Tekton Research Inc, Austin, 78745	32
Velocity Clinical Research, Lincoln, 68510	32
Headlands Research, Stockbridge, 30281	31
Hunan Provincial Center for Disease Control and Prevention, Changsha, 410005	31
Sundance Clinical Research, St. Louis, 63141	30
Benchmark Research New Orleans, Austin, 78705	29
Benchmark Research New Orleans, Fort Worth, 76135	28

© WCG Clinical 2025. All rights reserved.